Sertraline or placebo in chronic breathlessness? Lessons from placebo research

David C. Currow, Meera Agar, Magnus Ekström

Source: Eur Respir J, 53 (1) 1802316; 10.1183/13993003.02316-2018
Journal Issue: January

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
David C. Currow, Meera Agar, Magnus Ekström. Sertraline or placebo in chronic breathlessness? Lessons from placebo research. Eur Respir J, 53 (1) 1802316; 10.1183/13993003.02316-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Morphine for refractory breathlessness in COPD: a randomized clinical intervention study
Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Year: 2020


Is chronic breathlessness less recognised and treated compared with chronic pain? A case-based randomised controlled trial
Source: Eur Respir J, 52 (3) 1800887; 10.1183/13993003.00887-2018
Year: 2018



Symptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013


Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019




Effectiveness of a breathlessness service for patients suffering from breathlessness in advanced disease: pragmatic fast-track randomized controlled trial
Source: Virtual Congress 2020 – New and integrated tools for respiratory diagnosis and care
Year: 2020




Indacaterol once-daily improves day and night-time symptom control in COPD patients: a 26-week study versus placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial
Source: International Congress 2018 – Let’s interact and discuss the hot topics in pulmonary rehabilitation
Year: 2018




Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial
Source: Eur Respir J, 53 (1) 1801270; 10.1183/13993003.01270-2018
Year: 2019



48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013


Lung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studies
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013


Formoterol as relief medication in asthma: the jury is still out
Source: Eur Respir J 2003; 22: 723-724
Year: 2003


Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study
Source: Eur Respir J 2006; 28: Suppl. 50, 613s
Year: 2006

Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019


Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013


QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Efficacy of fluticasone on cough: a randomised controlled trial
Source: Eur Respir J 2005; 25: 147-152
Year: 2005